ID   KM20L2
AC   CVCL_D889
SY   KM-20L2; KM 20L2; KM 2012
DR   BTO; BTO:0005911
DR   BioSample; SAMN06481115
DR   cancercelllines; CVCL_D889
DR   ChEMBL-Cells; CHEMBL3307782
DR   ChEMBL-Targets; CHEMBL614791
DR   IARC_TP53; 28215
DR   NCI-DTP; KM 20L2
DR   PubChem_Cell_line; CVCL_D889
DR   Wikidata; Q54900067
RX   PubMed=2041050;
RX   PubMed=3349467;
RX   PubMed=15703300;
WW   https://iclac.org/wp-content/uploads/Cross-Contaminations_v12_distribution.xlsx
WW   https://dtp.cancer.gov/discovery_development/nci-60/cell_list.htm
CC   Problematic cell line: Contaminated. Shown to be a HT-29 derivative (PubMed=15703300; resulting in a decision not to include the cell line in the NCI60 panel).
CC   Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00514.
CC   Population: Caucasian.
CC   Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Glu853Ter (c.2557G>T); ClinVar=VCV001071632; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Thr1556Asnfs*3 (c.4666dupA) (c.4666_4667insA); ClinVar=VCV000428112; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Pro449Thr (c.1345C>A); ClinVar=VCV001333250; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 6770; SMAD4; Simple; p.Gln311Ter (c.931C>T); ClinVar=VCV000230663; Zygosity=Homozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273His (c.818G>A); ClinVar=VCV000012366; Zygosity=Homozygous (from parent cell line).
CC   Misspelling: KM202L; Note=Occasionally.
CC   Derived from site: In situ; Colon; UBERON=UBERON_0001155.
DI   NCIt; C4349; Colon adenocarcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_0320 ! HT-29
SX   Female
AG   44Y
CA   Cancer cell line
DT   Created: 22-10-12; Last updated: 05-10-23; Version: 29
//
RX   PubMed=2041050; DOI=10.1093/jnci/83.11.757;
RA   Monks A., Scudiero D.A., Skehan P., Shoemaker R.H., Paull K.D.,
RA   Vistica D.T., Hose C.D., Langley J., Cronise P., Vaigro-Wolff A.,
RA   Gray-Goodrich M., Campbell H., Mayo J.G., Boyd M.R.;
RT   "Feasibility of a high-flux anticancer drug screen using a diverse
RT   panel of cultured human tumor cell lines.";
RL   J. Natl. Cancer Inst. 83:757-766(1991).
//
RX   PubMed=3349467;
RA   Morikawa K., Walker S.M., Jessup J.M., Fidler I.J.;
RT   "In vivo selection of highly metastatic cells from surgical specimens
RT   of different primary human colon carcinomas implanted into nude
RT   mice.";
RL   Cancer Res. 48:1943-1948(1988).
//
RX   PubMed=15703300; DOI=10.1073/pnas.0405578102;
RA   Roschke A.V., Lababidi S., Tonon G., Gehlhaus K.S., Bussey K.J.,
RA   Weinstein J.N., Kirsch I.R.;
RT   "Karyotypic 'state' as a potential determinant for anticancer drug
RT   discovery.";
RL   Proc. Natl. Acad. Sci. U.S.A. 102:2964-2969(2005).
//